If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
Less is more for patients, practitioners, public and planet: a taxonomy for the harms of too much medicine ...
Ethnicity data are essential in understanding how different groups are impacted by different treatments/healthcare interventions, but more work is needed in how these data should be collected, handled ...
Joseph Alderman et al argue that predictive models in healthcare lack adequate oversight and regulation. They highlight the potential risks to patients and call for improved governance to ensure the ...
As a public health practitioner, you are considering how public health interventions might encourage individuals and families to reduce their salt intake to improve blood pressure among local ...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
Background Antibiotic over prescription for upper respiratory tract infections (URTIs) in primary care exacerbates antimicrobial resistance. There is a need for effective alternatives to antibiotic ...
14 Innovation Institute for Integration of Medicine and Engineering, West China Hospital, Sichuan University, chengdu, China Questionable research practice: a spectrum of questionable behaviours in ...
In clinical research, statistically significant effects do not necessarily indicate that an intervention provides benefits that are meaningful to patients. This is particularly important for ...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
Last 28 March 2025, the European Commission decided not to renew the conditional marketing authorisation for Translarna (ataluren) in Duchenne’s disease due to lack of efficacy after 11 years in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results